Health Condition 1: F42- Obsessive-compulsive disorder
Conditions
Interventions
Intervention1: Tab Vortioxetine as an add on molecule will be given with Tab Escitalopram: The Intervention population group will be initiated on treatment with Tab. Escitalopram
10mg, with dosage inc
Sponsors
Indican Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: i. Patients diagnosed with OCD as per ICD 11 by a psychiatrist ii. OCD rated as moderate to severe (YBOCS score 16+) iii. Patients who are drug naïve or have not taken any SRIs for the last 7 days at least.
Exclusion criteria
Exclusion criteria: i. Patients with psychotic symptoms ii. Patients with co-morbid major psychiatric illness iii. Patients with comorbid substance use disorder in dependence pattern except tobacco and caffeine. iv. Pregnant and lactating mothers. v. Patients with co-morbid medical or neurological illness vi. Patients with history of adverse drug reaction to Vortioxetine in the past
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the OCD symptoms measured by YBOCS (Yale Brown Obsessive Compulsive Scale).Timepoint: Follow-up assessments of all participants will be conducted at 4 weeks, 8 weeks and 12 weeks from their recruitment | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of Disease severity, extensive improvement or change in disease process and Efficacy index of the drug as measured by Clinical Global Impression Scale (CGI)Timepoint: Follow-up assessments of all participants will be conducted at 4 weeks, 8 weeks, and 12 weeks from their recruitment;To monitor the presence of any Adverse Drug reactions with Vortioxetine as measured by history clinical examination and Antidepressant Side effect Checklist Timepoint: Follow-up assessments of all participants will be conducted at 4 weeks, 8 weeks and 12 weeks from their recruitment | — |
Countries
India
Contacts
Public ContactKaushik Mukhopadhyay
AIIMS, Kalyani
Outcome results
None listed